{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-021512","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.345116+00:00","generated_at":"2026-06-04T23:30:14.560232+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cadrenal Therapeutics enters ATM agreement with H.C. Wainwright for up to $5.14M in common stock","bullets":["Entered ATM agreement with H.C. Wainwright to sell up to $5,143,730 of common stock from time to time.","Sales agent compensation is 3.0% of gross proceeds; no minimum sale obligation.","Offering subject to effectiveness of Form S-3 registration statement filed March 11, 2024.","Company can terminate agreement at any time; Wainwright can terminate on material adverse change."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-021512","json":"https://secwatch.observer/filing/0001213900-24-021512.json","markdown":"https://secwatch.observer/filing/0001213900-24-021512.md","text":"https://secwatch.observer/filing/0001213900-24-021512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024021512/0001213900-24-021512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024021512/ea0201524-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:30:14.560232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52691c4f3c4f26e4e54af41b7a4fc8e11052e2e0","claim":"Cadrenal Therapeutics, Inc. entered into At the Market Offering Agreement with H.C. Wainwright & Co., LLC valued at $5,143,730 (effective 2024-03-11).","evidence_excerpt":"On March 11, 2024, Cadrenal Therapeutics, Inc., a Delaware corporation, (the “Company”), entered into an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent to sell shares of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024021512/0001213900-24-021512-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"H.C. Wainwright & Co., LLC"},{"label":"Value","value":"$5,143,730"},{"label":"Effective","value":"2024-03-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}